View Future GrowthDOD Biotech 過去の業績過去 基準チェック /06DOD Biotechの収益は年間平均-27.4%の割合で減少していますが、 Personal Products業界の収益は年間 増加しています。収益は年間7.2% 13.6%割合で 減少しています。 DOD Biotechの自己資本利益率は1.4%であり、純利益率は2.1%です。主要情報-27.41%収益成長率-28.48%EPS成長率Personal Products 業界の成長3.67%収益成長率-13.58%株主資本利益率1.37%ネット・マージン2.13%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • Mar 01Full year 2025 earnings released: EPS: ฿0.10 (vs ฿0.07 in FY 2024)Full year 2025 results: EPS: ฿0.10 (up from ฿0.07 in FY 2024). Revenue: ฿621.2m (down 6.2% from FY 2024). Net income: ฿47.9m (up 51% from FY 2024). Profit margin: 7.7% (up from 4.8% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: ฿0.022 (vs ฿0.04 in 3Q 2024)Third quarter 2025 results: EPS: ฿0.022 (down from ฿0.04 in 3Q 2024). Revenue: ฿150.0m (down 16% from 3Q 2024). Net income: ฿10.1m (down 44% from 3Q 2024). Profit margin: 6.7% (down from 10.0% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 14Second quarter 2025 earnings released: EPS: ฿0.021 (vs ฿0.024 in 2Q 2024)Second quarter 2025 results: EPS: ฿0.021 (down from ฿0.024 in 2Q 2024). Revenue: ฿153.1m (flat on 2Q 2024). Net income: ฿9.68m (down 9.2% from 2Q 2024). Profit margin: 6.3% (down from 6.9% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Reported Earnings • May 10First quarter 2025 earnings released: EPS: ฿0.034 (vs ฿0.008 in 1Q 2024)First quarter 2025 results: EPS: ฿0.034 (up from ฿0.008 in 1Q 2024). Revenue: ฿173.2m (flat on 1Q 2024). Net income: ฿15.3m (up 340% from 1Q 2024). Profit margin: 8.9% (up from 2.0% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 21Full year 2024 earnings released: EPS: ฿0.07 (vs ฿0.13 in FY 2023)Full year 2024 results: EPS: ฿0.07 (down from ฿0.13 in FY 2023). Revenue: ฿662.0m (down 4.4% from FY 2023). Net income: ฿31.7m (down 46% from FY 2023). Profit margin: 4.8% (down from 8.4% in FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.Reported Earnings • Nov 12Third quarter 2024 earnings released: EPS: ฿0.039 (vs ฿0.033 in 3Q 2023)Third quarter 2024 results: EPS: ฿0.039 (up from ฿0.033 in 3Q 2023). Revenue: ฿179.5m (down 14% from 3Q 2023). Net income: ฿18.0m (up 22% from 3Q 2023). Profit margin: 10.0% (up from 7.1% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 41% per year, which means it has not declined as severely as earnings.すべての更新を表示Recent updatesNew Risk • May 22New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 185% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (฿729.7m market cap, or US$22.4m).Upcoming Dividend • Mar 06Upcoming dividend of ฿0.05 per shareEligible shareholders must have bought the stock before 13 March 2026. Payment date: 05 May 2026. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 2.9%. Lower than top quartile of Thai dividend payers (7.6%). Lower than average of industry peers (5.1%).Reported Earnings • Mar 01Full year 2025 earnings released: EPS: ฿0.10 (vs ฿0.07 in FY 2024)Full year 2025 results: EPS: ฿0.10 (up from ฿0.07 in FY 2024). Revenue: ฿621.2m (down 6.2% from FY 2024). Net income: ฿47.9m (up 51% from FY 2024). Profit margin: 7.7% (up from 4.8% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.お知らせ • Feb 27+ 1 more updateDOD Biotech Public Company Limited announces Annual dividend, payable on May 05, 2026DOD Biotech Public Company Limited announced Annual dividend of THB 0.0500 per share payable on May 05, 2026, ex-date on March 13, 2026 and record date on March 16, 2026.New Risk • Feb 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Thai stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 35% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Profit margins are more than 30% lower than last year (5.5% net profit margin). Market cap is less than US$100m (฿819.8m market cap, or US$26.3m).Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ฿1.82, the stock trades at a trailing P/E ratio of 23.7x. Average trailing P/E is 14x in the Personal Products industry in Thailand. Total loss to shareholders of 67% over the past three years.New Risk • Nov 19New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.5% Last year net profit margin: 8.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 35% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (5.5% net profit margin). Market cap is less than US$100m (฿738.7m market cap, or US$22.8m).Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: ฿0.022 (vs ฿0.04 in 3Q 2024)Third quarter 2025 results: EPS: ฿0.022 (down from ฿0.04 in 3Q 2024). Revenue: ฿150.0m (down 16% from 3Q 2024). Net income: ฿10.1m (down 44% from 3Q 2024). Profit margin: 6.7% (down from 10.0% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ฿2.00, the stock trades at a trailing P/E ratio of 20.2x. Average trailing P/E is 17x in the Personal Products industry in Thailand. Total loss to shareholders of 63% over the past three years.Reported Earnings • Aug 14Second quarter 2025 earnings released: EPS: ฿0.021 (vs ฿0.024 in 2Q 2024)Second quarter 2025 results: EPS: ฿0.021 (down from ฿0.024 in 2Q 2024). Revenue: ฿153.1m (flat on 2Q 2024). Net income: ฿9.68m (down 9.2% from 2Q 2024). Profit margin: 6.3% (down from 6.9% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ฿2.08, the stock trades at a trailing P/E ratio of 29.2x. Average trailing P/E is 20x in the Personal Products industry in Thailand. Total loss to shareholders of 60% over the past three years.Valuation Update With 7 Day Price Move • Jun 12Investor sentiment improves as stock rises 26%After last week's 26% share price gain to ฿1.99, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 21x in the Personal Products industry in Thailand. Total loss to shareholders of 68% over the past three years.Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ฿1.68, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 20x in the Personal Products industry in Thailand. Total loss to shareholders of 75% over the past three years.New Risk • May 17New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.8% Last year net profit margin: 12% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.8% net profit margin). Market cap is less than US$100m (฿963.9m market cap, or US$28.9m).Buy Or Sell Opportunity • May 15Now 24% undervaluedOver the last 90 days, the stock has risen 52% to ฿2.02. The fair value is estimated to be ฿2.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 25%.Reported Earnings • May 10First quarter 2025 earnings released: EPS: ฿0.034 (vs ฿0.008 in 1Q 2024)First quarter 2025 results: EPS: ฿0.034 (up from ฿0.008 in 1Q 2024). Revenue: ฿173.2m (flat on 1Q 2024). Net income: ฿15.3m (up 340% from 1Q 2024). Profit margin: 8.9% (up from 2.0% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.New Risk • May 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Thai stocks, typically moving 4.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 39% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (4.2% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.8% net profit margin). Market cap is less than US$100m (฿531.5m market cap, or US$16.1m).Valuation Update With 7 Day Price Move • May 09Investor sentiment improves as stock rises 29%After last week's 29% share price gain to ฿1.54, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 17x in the Personal Products industry in Thailand. Total loss to shareholders of 73% over the past three years.Reported Earnings • Feb 21Full year 2024 earnings released: EPS: ฿0.07 (vs ฿0.13 in FY 2023)Full year 2024 results: EPS: ฿0.07 (down from ฿0.13 in FY 2023). Revenue: ฿662.0m (down 4.4% from FY 2023). Net income: ฿31.7m (down 46% from FY 2023). Profit margin: 4.8% (down from 8.4% in FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 20DOD Biotech Public Company Limited, Annual General Meeting, Apr 28, 2025DOD Biotech Public Company Limited, Annual General Meeting, Apr 28, 2025, at 14:00 SE Asia Standard Time. Location: arrange a meeting in the format of an, ThailandNew Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Thai stocks, typically moving 10.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10.0% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (฿999.9m market cap, or US$28.8m).Reported Earnings • Nov 12Third quarter 2024 earnings released: EPS: ฿0.039 (vs ฿0.033 in 3Q 2023)Third quarter 2024 results: EPS: ฿0.039 (up from ฿0.033 in 3Q 2023). Revenue: ฿179.5m (down 14% from 3Q 2023). Net income: ฿18.0m (up 22% from 3Q 2023). Profit margin: 10.0% (up from 7.1% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 41% per year, which means it has not declined as severely as earnings.お知らせ • Aug 19DOD Biotech Public Company Limited Appoints Porntep Siriwanarangsun as an Independent Director, Effective September 1, 2024DOD Biotech Public Company Limited announced the resolution of the Board of Directors Meeting No. 9/2567, held on August 16, 2024. The meeting resolved to appoint Dr. Porntep Siriwanarangsun as an Independent Director, replacing the resigning director, effective from September 1, 2024, onwards.Reported Earnings • Aug 10Second quarter 2024 earnings released: ฿0.37 loss per share (vs ฿0.018 profit in 2Q 2023)Second quarter 2024 results: ฿0.37 loss per share (down from ฿0.018 profit in 2Q 2023). Revenue: ฿156.8m (down 18% from 2Q 2023). Net loss: ฿166.6m (down ฿174.6m from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Jun 19Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ฿1.88, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 21x in the Personal Products industry in Thailand. Total loss to shareholders of 87% over the past three years.Valuation Update With 7 Day Price Move • Jun 18Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ฿1.88, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 20x in the Personal Products industry in Thailand. Total loss to shareholders of 87% over the past three years.New Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Thai stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (฿873.8m market cap, or US$23.8m).New Risk • May 29New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 65% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 43% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (฿1.14b market cap, or US$30.9m).Reported Earnings • May 11First quarter 2024 earnings released: EPS: ฿0.013 (vs ฿0.034 loss in 1Q 2023)First quarter 2024 results: EPS: ฿0.013 (up from ฿0.034 loss in 1Q 2023). Revenue: ฿172.1m (up 41% from 1Q 2023). Net income: ฿3.49m (up ฿17.3m from 1Q 2023). Profit margin: 2.0% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 24Full year 2023 earnings released: EPS: ฿0.056 (vs ฿0.84 loss in FY 2022)Full year 2023 results: EPS: ฿0.056 (up from ฿0.84 loss in FY 2022). Revenue: ฿710.1m (up 30% from FY 2022). Net income: ฿20.2m (up ฿363.2m from FY 2022). Profit margin: 2.8% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.お知らせ • Feb 23DOD Biotech Public Company Limited, Annual General Meeting, Apr 25, 2024DOD Biotech Public Company Limited, Annual General Meeting, Apr 25, 2024, at 14:00 Indian Standard Time. Location: Meeting Room no.1, DOD Biotech Public Company Limited, no. 111 Moo 2, Tha Chin Subdistrict, Mueang Samut Sakhon 74000 Samut Sakhon Thailand Agenda: To consider and acknowledge the Company's performance for the year 2023; to consider and approve the Company's audited the financial statements for the year ended December 31, 2023; to consider and acknowledge the omission of dividend payments for the year 2023; to consideration and approval of Transferring share premium to Offset accumulated Company Losses; and to discuss other matters.Reported Earnings • Nov 10Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: ฿207.8m (up 23% from 3Q 2022). Net income: ฿14.8m (up 243% from 3Q 2022). Profit margin: 7.1% (up from 2.6% in 3Q 2022). The increase in margin was driven by higher revenue.Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: ฿0.018 (vs ฿0.011 in 2Q 2022)Second quarter 2023 results: EPS: ฿0.018 (up from ฿0.011 in 2Q 2022). Revenue: ฿191.2m (up 40% from 2Q 2022). Net income: ฿7.93m (up 77% from 2Q 2022). Profit margin: 4.1% (up from 3.3% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.お知らせ • Jun 14DOD Biotech Public Company Limited has completed a Follow-on Equity Offering in the amount of THB 202.208528 million.DOD Biotech Public Company Limited has completed a Follow-on Equity Offering in the amount of THB 202.208528 million. Security Name: Shares Security Type: Common Stock Securities Offered: 25,552,382 Price\Range: THB 4 Security Name: Shares Security Type: Common Stock Securities Offered: 24,390,000 Price\Range: THB 4.1 Transaction Features: Rights Offering; Subsequent Direct ListingReported Earnings • Feb 25Full year 2022 earnings released: ฿0.83 loss per share (vs ฿0.58 profit in FY 2021)Full year 2022 results: ฿0.83 loss per share (down from ฿0.58 profit in FY 2021). Revenue: ฿548.3m (down 46% from FY 2021). Net loss: ฿343.0m (down 245% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ฿5.75, the stock trades at a trailing P/E ratio of 46.1x. Average trailing P/E is 42x in the Personal Products industry in Thailand. Total loss to shareholders of 26% over the past three years.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ฿6.35, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 39x in the Personal Products industry in Thailand. Total loss to shareholders of 40% over the past three years.Reported Earnings • May 15First quarter 2022 earnings released: EPS: ฿0.014 (vs ฿0.40 in 1Q 2021)First quarter 2022 results: EPS: ฿0.014 (down from ฿0.40 in 1Q 2021). Revenue: ฿161.4m (down 55% from 1Q 2021). Net income: ฿4.99m (down 97% from 1Q 2021). Profit margin: 3.1% (down from 46% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 27Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: ฿0.57 (up from ฿0.34 in FY 2020). Revenue: ฿1.02b (down 37% from FY 2020). Net income: ฿237.2m (up 68% from FY 2020). Profit margin: 23% (up from 8.7% in FY 2020). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 42%. Over the next year, revenue is forecast to grow 81%, compared to a 11% growth forecast for the industry in Thailand. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Feb 25Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ฿9.45, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 20x in the Personal Products industry in Asia. Total loss to shareholders of 14% over the past three years.Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS ฿0.065 (vs ฿0.17 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ฿185.4m (down 53% from 3Q 2020). Net income: ฿28.5m (down 59% from 3Q 2020). Profit margin: 15% (down from 18% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 13Second quarter 2021 earnings released: EPS ฿0.037 (vs ฿0.18 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ฿248.1m (down 43% from 2Q 2020). Net income: ฿15.3m (down 80% from 2Q 2020). Profit margin: 6.2% (down from 18% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Reported Earnings • May 12First quarter 2021 earnings released: EPS ฿0.13 (vs ฿0.068 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ฿412.9m (up 20% from 1Q 2020). Net income: ฿55.1m (up 97% from 1Q 2020). Profit margin: 13% (up from 8.1% in 1Q 2020).Reported Earnings • Mar 02Full year 2020 earnings released: EPS ฿0.34 (vs ฿0.21 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: ฿1.62b (up 104% from FY 2019). Net income: ฿141.3m (up 63% from FY 2019). Profit margin: 8.7% (down from 11% in FY 2019).Is New 90 Day High Low • Feb 19New 90-day high: ฿13.60The company is up 58% from its price of ฿8.60 on 20 November 2020. The Thai market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 27% over the same period.Valuation Update With 7 Day Price Move • Jan 28Investor sentiment improved over the past weekAfter last week's 19% share price gain to ฿11.00, the stock is trading at a trailing P/E ratio of 24.9x, up from the previous P/E ratio of 21x. This compares to an average P/E of 23x in the Personal Products industry in Thailand. Total returns to shareholders over the past year are 52%.Is New 90 Day High Low • Jan 28New 90-day high: ฿11.00The company is up 26% from its price of ฿8.75 on 30 October 2020. The Thai market is up 25% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 22% over the same period.Is New 90 Day High Low • Jan 06New 90-day high: ฿10.00The company is up 6.0% from its price of ฿9.40 on 08 October 2020. The Thai market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period.Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS ฿0.17The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ฿393.7m (up 79% from 3Q 2019). Net income: ฿69.5m (up 247% from 3Q 2019). Profit margin: 18% (up from 9.1% in 3Q 2019). The increase in margin was driven by higher revenue.収支内訳DOD Biotech の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史SET:DOD 収益、費用、利益 ( )THB Millions日付収益収益G+A経費研究開発費31 Mar 2657112181031 Dec 2562148183030 Sep 2563335185030 Jun 2566245187031 Mar 2566532193031 Dec 2466232209030 Sep 2469158214030 Jun 2470754220031 Mar 2474187204031 Dec 2369358199030 Sep 23588-324185030 Jun 23562-336168031 Mar 23509-362174031 Dec 22548-343163030 Sep 2269651164030 Jun 2271376158031 Mar 2282487144031 Dec 211,018237128030 Sep 211,171311112030 Jun 211,276367107031 Mar 211,254412108031 Dec 201,080280107030 Sep 201,024177238030 Jun 20953112308031 Mar 2085668325031 Dec 1979687330030 Sep 1953588199030 Jun 19472141124031 Mar 19577235112031 Dec 18670305105030 Sep 18701323107030 Jun 18621277100031 Mar 1850622087031 Dec 1738914283030 Sep 1736813073031 Dec 1636813960031 Dec 15385129500質の高い収益: DODにはTHB5.0M } という大きな 一回限りの 利益があり、過去 12 か月の財務実績が31st March, 2026に影響を及ぼしています。利益率の向上: DODの現在の純利益率 (2.1%)は、昨年(4.8%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: DODの収益は過去 5 年間で年間27.4%減少しました。成長の加速: DODは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: DODは過去 1 年間で収益成長率がマイナス ( -62.1% ) となったため、 Personal Products業界平均 ( 6.4% ) と比較することが困難です。株主資本利益率高いROE: DODの 自己資本利益率 ( 1.4% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHousehold 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 16:12終値2026/06/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DOD Biotech Public Company Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Wilasinee BoonmasungsongGloblex Securities Co. Ltd.Hathaichanoke MoonwongPhillip Securities (Thailand) PCLApichat PoobunjirdkulTisco Securities Co. Ltd.1 その他のアナリストを表示
Reported Earnings • Mar 01Full year 2025 earnings released: EPS: ฿0.10 (vs ฿0.07 in FY 2024)Full year 2025 results: EPS: ฿0.10 (up from ฿0.07 in FY 2024). Revenue: ฿621.2m (down 6.2% from FY 2024). Net income: ฿47.9m (up 51% from FY 2024). Profit margin: 7.7% (up from 4.8% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: ฿0.022 (vs ฿0.04 in 3Q 2024)Third quarter 2025 results: EPS: ฿0.022 (down from ฿0.04 in 3Q 2024). Revenue: ฿150.0m (down 16% from 3Q 2024). Net income: ฿10.1m (down 44% from 3Q 2024). Profit margin: 6.7% (down from 10.0% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 14Second quarter 2025 earnings released: EPS: ฿0.021 (vs ฿0.024 in 2Q 2024)Second quarter 2025 results: EPS: ฿0.021 (down from ฿0.024 in 2Q 2024). Revenue: ฿153.1m (flat on 2Q 2024). Net income: ฿9.68m (down 9.2% from 2Q 2024). Profit margin: 6.3% (down from 6.9% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Reported Earnings • May 10First quarter 2025 earnings released: EPS: ฿0.034 (vs ฿0.008 in 1Q 2024)First quarter 2025 results: EPS: ฿0.034 (up from ฿0.008 in 1Q 2024). Revenue: ฿173.2m (flat on 1Q 2024). Net income: ฿15.3m (up 340% from 1Q 2024). Profit margin: 8.9% (up from 2.0% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 21Full year 2024 earnings released: EPS: ฿0.07 (vs ฿0.13 in FY 2023)Full year 2024 results: EPS: ฿0.07 (down from ฿0.13 in FY 2023). Revenue: ฿662.0m (down 4.4% from FY 2023). Net income: ฿31.7m (down 46% from FY 2023). Profit margin: 4.8% (down from 8.4% in FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Nov 12Third quarter 2024 earnings released: EPS: ฿0.039 (vs ฿0.033 in 3Q 2023)Third quarter 2024 results: EPS: ฿0.039 (up from ฿0.033 in 3Q 2023). Revenue: ฿179.5m (down 14% from 3Q 2023). Net income: ฿18.0m (up 22% from 3Q 2023). Profit margin: 10.0% (up from 7.1% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 41% per year, which means it has not declined as severely as earnings.
New Risk • May 22New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 185% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (฿729.7m market cap, or US$22.4m).
Upcoming Dividend • Mar 06Upcoming dividend of ฿0.05 per shareEligible shareholders must have bought the stock before 13 March 2026. Payment date: 05 May 2026. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 2.9%. Lower than top quartile of Thai dividend payers (7.6%). Lower than average of industry peers (5.1%).
Reported Earnings • Mar 01Full year 2025 earnings released: EPS: ฿0.10 (vs ฿0.07 in FY 2024)Full year 2025 results: EPS: ฿0.10 (up from ฿0.07 in FY 2024). Revenue: ฿621.2m (down 6.2% from FY 2024). Net income: ฿47.9m (up 51% from FY 2024). Profit margin: 7.7% (up from 4.8% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
お知らせ • Feb 27+ 1 more updateDOD Biotech Public Company Limited announces Annual dividend, payable on May 05, 2026DOD Biotech Public Company Limited announced Annual dividend of THB 0.0500 per share payable on May 05, 2026, ex-date on March 13, 2026 and record date on March 16, 2026.
New Risk • Feb 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Thai stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 35% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Profit margins are more than 30% lower than last year (5.5% net profit margin). Market cap is less than US$100m (฿819.8m market cap, or US$26.3m).
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ฿1.82, the stock trades at a trailing P/E ratio of 23.7x. Average trailing P/E is 14x in the Personal Products industry in Thailand. Total loss to shareholders of 67% over the past three years.
New Risk • Nov 19New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.5% Last year net profit margin: 8.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 35% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (5.5% net profit margin). Market cap is less than US$100m (฿738.7m market cap, or US$22.8m).
Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: ฿0.022 (vs ฿0.04 in 3Q 2024)Third quarter 2025 results: EPS: ฿0.022 (down from ฿0.04 in 3Q 2024). Revenue: ฿150.0m (down 16% from 3Q 2024). Net income: ฿10.1m (down 44% from 3Q 2024). Profit margin: 6.7% (down from 10.0% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ฿2.00, the stock trades at a trailing P/E ratio of 20.2x. Average trailing P/E is 17x in the Personal Products industry in Thailand. Total loss to shareholders of 63% over the past three years.
Reported Earnings • Aug 14Second quarter 2025 earnings released: EPS: ฿0.021 (vs ฿0.024 in 2Q 2024)Second quarter 2025 results: EPS: ฿0.021 (down from ฿0.024 in 2Q 2024). Revenue: ฿153.1m (flat on 2Q 2024). Net income: ฿9.68m (down 9.2% from 2Q 2024). Profit margin: 6.3% (down from 6.9% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ฿2.08, the stock trades at a trailing P/E ratio of 29.2x. Average trailing P/E is 20x in the Personal Products industry in Thailand. Total loss to shareholders of 60% over the past three years.
Valuation Update With 7 Day Price Move • Jun 12Investor sentiment improves as stock rises 26%After last week's 26% share price gain to ฿1.99, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 21x in the Personal Products industry in Thailand. Total loss to shareholders of 68% over the past three years.
Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ฿1.68, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 20x in the Personal Products industry in Thailand. Total loss to shareholders of 75% over the past three years.
New Risk • May 17New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.8% Last year net profit margin: 12% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.8% net profit margin). Market cap is less than US$100m (฿963.9m market cap, or US$28.9m).
Buy Or Sell Opportunity • May 15Now 24% undervaluedOver the last 90 days, the stock has risen 52% to ฿2.02. The fair value is estimated to be ฿2.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 25%.
Reported Earnings • May 10First quarter 2025 earnings released: EPS: ฿0.034 (vs ฿0.008 in 1Q 2024)First quarter 2025 results: EPS: ฿0.034 (up from ฿0.008 in 1Q 2024). Revenue: ฿173.2m (flat on 1Q 2024). Net income: ฿15.3m (up 340% from 1Q 2024). Profit margin: 8.9% (up from 2.0% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
New Risk • May 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Thai stocks, typically moving 4.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 39% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (4.2% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.8% net profit margin). Market cap is less than US$100m (฿531.5m market cap, or US$16.1m).
Valuation Update With 7 Day Price Move • May 09Investor sentiment improves as stock rises 29%After last week's 29% share price gain to ฿1.54, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 17x in the Personal Products industry in Thailand. Total loss to shareholders of 73% over the past three years.
Reported Earnings • Feb 21Full year 2024 earnings released: EPS: ฿0.07 (vs ฿0.13 in FY 2023)Full year 2024 results: EPS: ฿0.07 (down from ฿0.13 in FY 2023). Revenue: ฿662.0m (down 4.4% from FY 2023). Net income: ฿31.7m (down 46% from FY 2023). Profit margin: 4.8% (down from 8.4% in FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 20DOD Biotech Public Company Limited, Annual General Meeting, Apr 28, 2025DOD Biotech Public Company Limited, Annual General Meeting, Apr 28, 2025, at 14:00 SE Asia Standard Time. Location: arrange a meeting in the format of an, Thailand
New Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Thai stocks, typically moving 10.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10.0% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (฿999.9m market cap, or US$28.8m).
Reported Earnings • Nov 12Third quarter 2024 earnings released: EPS: ฿0.039 (vs ฿0.033 in 3Q 2023)Third quarter 2024 results: EPS: ฿0.039 (up from ฿0.033 in 3Q 2023). Revenue: ฿179.5m (down 14% from 3Q 2023). Net income: ฿18.0m (up 22% from 3Q 2023). Profit margin: 10.0% (up from 7.1% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 41% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 19DOD Biotech Public Company Limited Appoints Porntep Siriwanarangsun as an Independent Director, Effective September 1, 2024DOD Biotech Public Company Limited announced the resolution of the Board of Directors Meeting No. 9/2567, held on August 16, 2024. The meeting resolved to appoint Dr. Porntep Siriwanarangsun as an Independent Director, replacing the resigning director, effective from September 1, 2024, onwards.
Reported Earnings • Aug 10Second quarter 2024 earnings released: ฿0.37 loss per share (vs ฿0.018 profit in 2Q 2023)Second quarter 2024 results: ฿0.37 loss per share (down from ฿0.018 profit in 2Q 2023). Revenue: ฿156.8m (down 18% from 2Q 2023). Net loss: ฿166.6m (down ฿174.6m from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Jun 19Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ฿1.88, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 21x in the Personal Products industry in Thailand. Total loss to shareholders of 87% over the past three years.
Valuation Update With 7 Day Price Move • Jun 18Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ฿1.88, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 20x in the Personal Products industry in Thailand. Total loss to shareholders of 87% over the past three years.
New Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Thai stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (฿873.8m market cap, or US$23.8m).
New Risk • May 29New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 65% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 43% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (฿1.14b market cap, or US$30.9m).
Reported Earnings • May 11First quarter 2024 earnings released: EPS: ฿0.013 (vs ฿0.034 loss in 1Q 2023)First quarter 2024 results: EPS: ฿0.013 (up from ฿0.034 loss in 1Q 2023). Revenue: ฿172.1m (up 41% from 1Q 2023). Net income: ฿3.49m (up ฿17.3m from 1Q 2023). Profit margin: 2.0% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 24Full year 2023 earnings released: EPS: ฿0.056 (vs ฿0.84 loss in FY 2022)Full year 2023 results: EPS: ฿0.056 (up from ฿0.84 loss in FY 2022). Revenue: ฿710.1m (up 30% from FY 2022). Net income: ฿20.2m (up ฿363.2m from FY 2022). Profit margin: 2.8% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 23DOD Biotech Public Company Limited, Annual General Meeting, Apr 25, 2024DOD Biotech Public Company Limited, Annual General Meeting, Apr 25, 2024, at 14:00 Indian Standard Time. Location: Meeting Room no.1, DOD Biotech Public Company Limited, no. 111 Moo 2, Tha Chin Subdistrict, Mueang Samut Sakhon 74000 Samut Sakhon Thailand Agenda: To consider and acknowledge the Company's performance for the year 2023; to consider and approve the Company's audited the financial statements for the year ended December 31, 2023; to consider and acknowledge the omission of dividend payments for the year 2023; to consideration and approval of Transferring share premium to Offset accumulated Company Losses; and to discuss other matters.
Reported Earnings • Nov 10Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: ฿207.8m (up 23% from 3Q 2022). Net income: ฿14.8m (up 243% from 3Q 2022). Profit margin: 7.1% (up from 2.6% in 3Q 2022). The increase in margin was driven by higher revenue.
Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: ฿0.018 (vs ฿0.011 in 2Q 2022)Second quarter 2023 results: EPS: ฿0.018 (up from ฿0.011 in 2Q 2022). Revenue: ฿191.2m (up 40% from 2Q 2022). Net income: ฿7.93m (up 77% from 2Q 2022). Profit margin: 4.1% (up from 3.3% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.
お知らせ • Jun 14DOD Biotech Public Company Limited has completed a Follow-on Equity Offering in the amount of THB 202.208528 million.DOD Biotech Public Company Limited has completed a Follow-on Equity Offering in the amount of THB 202.208528 million. Security Name: Shares Security Type: Common Stock Securities Offered: 25,552,382 Price\Range: THB 4 Security Name: Shares Security Type: Common Stock Securities Offered: 24,390,000 Price\Range: THB 4.1 Transaction Features: Rights Offering; Subsequent Direct Listing
Reported Earnings • Feb 25Full year 2022 earnings released: ฿0.83 loss per share (vs ฿0.58 profit in FY 2021)Full year 2022 results: ฿0.83 loss per share (down from ฿0.58 profit in FY 2021). Revenue: ฿548.3m (down 46% from FY 2021). Net loss: ฿343.0m (down 245% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ฿5.75, the stock trades at a trailing P/E ratio of 46.1x. Average trailing P/E is 42x in the Personal Products industry in Thailand. Total loss to shareholders of 26% over the past three years.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ฿6.35, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 39x in the Personal Products industry in Thailand. Total loss to shareholders of 40% over the past three years.
Reported Earnings • May 15First quarter 2022 earnings released: EPS: ฿0.014 (vs ฿0.40 in 1Q 2021)First quarter 2022 results: EPS: ฿0.014 (down from ฿0.40 in 1Q 2021). Revenue: ฿161.4m (down 55% from 1Q 2021). Net income: ฿4.99m (down 97% from 1Q 2021). Profit margin: 3.1% (down from 46% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 27Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: ฿0.57 (up from ฿0.34 in FY 2020). Revenue: ฿1.02b (down 37% from FY 2020). Net income: ฿237.2m (up 68% from FY 2020). Profit margin: 23% (up from 8.7% in FY 2020). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 42%. Over the next year, revenue is forecast to grow 81%, compared to a 11% growth forecast for the industry in Thailand. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ฿9.45, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 20x in the Personal Products industry in Asia. Total loss to shareholders of 14% over the past three years.
Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS ฿0.065 (vs ฿0.17 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ฿185.4m (down 53% from 3Q 2020). Net income: ฿28.5m (down 59% from 3Q 2020). Profit margin: 15% (down from 18% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 13Second quarter 2021 earnings released: EPS ฿0.037 (vs ฿0.18 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ฿248.1m (down 43% from 2Q 2020). Net income: ฿15.3m (down 80% from 2Q 2020). Profit margin: 6.2% (down from 18% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 12First quarter 2021 earnings released: EPS ฿0.13 (vs ฿0.068 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ฿412.9m (up 20% from 1Q 2020). Net income: ฿55.1m (up 97% from 1Q 2020). Profit margin: 13% (up from 8.1% in 1Q 2020).
Reported Earnings • Mar 02Full year 2020 earnings released: EPS ฿0.34 (vs ฿0.21 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: ฿1.62b (up 104% from FY 2019). Net income: ฿141.3m (up 63% from FY 2019). Profit margin: 8.7% (down from 11% in FY 2019).
Is New 90 Day High Low • Feb 19New 90-day high: ฿13.60The company is up 58% from its price of ฿8.60 on 20 November 2020. The Thai market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 27% over the same period.
Valuation Update With 7 Day Price Move • Jan 28Investor sentiment improved over the past weekAfter last week's 19% share price gain to ฿11.00, the stock is trading at a trailing P/E ratio of 24.9x, up from the previous P/E ratio of 21x. This compares to an average P/E of 23x in the Personal Products industry in Thailand. Total returns to shareholders over the past year are 52%.
Is New 90 Day High Low • Jan 28New 90-day high: ฿11.00The company is up 26% from its price of ฿8.75 on 30 October 2020. The Thai market is up 25% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 22% over the same period.
Is New 90 Day High Low • Jan 06New 90-day high: ฿10.00The company is up 6.0% from its price of ฿9.40 on 08 October 2020. The Thai market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period.
Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS ฿0.17The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ฿393.7m (up 79% from 3Q 2019). Net income: ฿69.5m (up 247% from 3Q 2019). Profit margin: 18% (up from 9.1% in 3Q 2019). The increase in margin was driven by higher revenue.